So Yeon Paek, MD
Dermatology · Dallas, TXNPI 1790079184
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $584,053 of the $812,160 with a category attached, or 71.9%. 45 manufacturers reported payments, led by AbbVie at 58.3% of the total. 2025 is the largest year on record at $200,352, 2.1 times the $94,443 reported in 2019. Among dermatology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,389 payments — averaging $584.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$473K
- Johnson & Johnson$103K
- UCB, Inc.$92K
- Janssen Scientific Affairs, LLC$78K
- Novartis$34K
- Incyte Corporation$19K
- plus $12K from 39 others
Across 1,469 payments — averaging $1808.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.2M
- Incyte Corporation$787K
- Amgen$285K
- E.r. Squibb & Sons, L.L.C.$174K
- Janssen Research & Development, LLC$152K
- UCB SA$39K
- plus $11K from 2 others
What the payments were for
- Consulting fees$125,88415%
- Speaking & faculty fees$584,05372%
- Travel & lodging$75,0439%
- Food & beverage$26,7563%
- Education$4240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rinvoq$333,491
- Tremfya$177,312
- Bimzelx$83,479
- Humira$65,195
- Skyrizi$60,708
- COSENTYX$25,563
- OPZELURA$18,425
- SILIQ$2,104
- DUPIXENT$863
- Kerecis Omega3 Marigen$351
- ARAZLO$304
- Cabtreo$152
- DUOBRII$152
- Kerecis Omega3 SurgiClose$117
- Kerecis Omega3 GraftGuide$117
How this compares
$812,160 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 14 | $191,691 |
| Ketoconazole | 42 | $612 |
| Clobetasol Propionate | 25 | $574 |
| Triamcinolone Acetonide | 41 | $455 |
| Nystatin | 13 | $245 |
| Terbinafine Hcl | 14 | $172 |
| Mupirocin | 14 | $106 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Dallas
- Jennifer CatherDallas$1.3M
- Ross RaduskyDallas$1.2M
- Joseph MerolaDallas$1.2M
- Martin MenterDallas$512K
- Mary HornerDallas$448K
- Donald GlassDallas$347K
- William AbramovitsDallas$325K
- Mary FleischliDallas$153K
- Adean KingstonDallas$141K
- Edward LainAustin$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.